Literature DB >> 22012216

Chronic phase of Chagas disease: why should it be treated? A comprehensive review.

José Rodrigues Coura1, José Borges-Pereira.   

Abstract

The pathogenesis and evolutive pattern of Chagas disease suggests that the chronic phase should be more widely treated in order to (i) eliminate Trypanosoma cruzi and prevent new inflammatory foci and the extension of tissue lesions, (ii) promote tissue regeneration to prevent fibrosis, (iii) reverse existing fibrosis, (iv) prevent cardiomyopathy, megaoesophagus and megacolon and (v) reduce or eliminate cardiac block and arrhythmia. All cases of the indeterminate chronic form of Chagas disease without contraindications due to other concomitant diseases or pregnancy should be treated and not only cases involving children or recently infected cases. Patients with chronic Chagas cardiomyopathy grade II of the New York Heart Association classification should be treated with specific chemotherapy and grade III can be treated according to medical-patient decisions. We are proposing the following new strategies for chemotherapeutic treatment of the chronic phase of Chagas disease: (i) repeated short-term treatments for 30 consecutive days and interval of 30-60 days for six months to one year and (ii) combinations of drugs with different mechanisms of action, such as benznidazole + nifurtimox, benznidazole or nifurtimox + allopurinol or triazole antifungal agents, inhibition of sterol synthesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22012216     DOI: 10.1590/s0074-02762011000600001

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  39 in total

1.  Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment.

Authors:  José A Pérez-Molina; Francesca Norman; Rogelio López-Vélez
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

2.  Success of benznidazole chemotherapy in chronic Trypanosoma cruzi-infected patients with a sustained negative PCR result.

Authors:  L Murcia; B Carrilero; F Ferrer; M Roig; F Franco; M Segovia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-04       Impact factor: 3.267

3.  Enalapril in Combination with Benznidazole Reduces Cardiac Inflammation and Creatine Kinases in Mice Chronically Infected with Trypanosoma cruzi.

Authors:  Arlete Rita Penitente; Ana Luísa Junqueira Leite; Guilherme de Paula Costa; Deena Shrestha; Aline Luciano Horta; Antônio J Natali; Clóvis A Neves; Andre Talvani
Journal:  Am J Trop Med Hyg       Date:  2015-09-08       Impact factor: 2.345

4.  Opportunities and challenges in chronic Chagas cardiomyopathy.

Authors:  George A Mensah; Kristin M Burns; Emmanuel K Peprah; Uchechukwu K A Sampson; Michael M Engelgau
Journal:  Glob Heart       Date:  2015-09

5.  Expanding the binding envelope of CYP51 inhibitors targeting Trypanosoma cruzi with 4-aminopyridyl-based sulfonamide derivatives.

Authors:  Debora F Vieira; Jun Yong Choi; William R Roush; Larissa M Podust
Journal:  Chembiochem       Date:  2014-04-25       Impact factor: 3.164

Review 6.  Diagnosis and management of Chagas disease and cardiomyopathy.

Authors:  Antonio L Ribeiro; Maria P Nunes; Mauro M Teixeira; Manoel O C Rocha
Journal:  Nat Rev Cardiol       Date:  2012-07-31       Impact factor: 32.419

7.  Benznidazole Extended-Release Tablets for Improved Treatment of Chagas Disease: Preclinical Pharmacokinetic Study.

Authors:  Marcelo Gomes Davanço; Michel Leandro Campos; Talita Atanazio Rosa; Elias Carvalho Padilha; Alejandro Henao Alzate; Larissa Araújo Rolim; Pedro José Rolim-Neto; Rosângela Gonçalves Peccinini
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

8.  A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention.

Authors:  Girley Francisco Machado-de-Assis; Glaucia Alessio Diniz; Roberto Araújo Montoya; João Carlos Pinto Dias; José Rodrigues Coura; George Luiz Lins Machado-Coelho; Pedro Albajar-Viñas; Rosália Morais Torres; Marta de Lana
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-11       Impact factor: 2.743

9.  New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice.

Authors:  Juan M Bustamante; Julie M Craft; Byron D Crowe; Sarah A Ketchie; Rick L Tarleton
Journal:  J Infect Dis       Date:  2013-08-14       Impact factor: 5.226

10.  Fexinidazole: a potential new drug candidate for Chagas disease.

Authors:  Maria Terezinha Bahia; Isabel Mayer de Andrade; Tassiane Assíria Fontes Martins; Álvaro Fernando da Silva do Nascimento; Lívia de Figueiredo Diniz; Ivo Santana Caldas; André Talvani; Bernadette Bourdin Trunz; Els Torreele; Isabela Ribeiro
Journal:  PLoS Negl Trop Dis       Date:  2012-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.